This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

5 Oct 2021

Thermo Fisher takes on operational responsibility for new Swiss biologics manufacturing site

The 1.5 million-sq. ft Switzerland-based facility is part of the company's strategic partnership with CSL Limited

As part of a wider partnership agreement made last year with CSL Limited, Thermo Fisher Scientific has now assumed operational responsibility for a recently constructed biologics manufacturing facility in Lengnau, Switzerland.

Through the long-term lease arrangement, the 1.5 million-sq. ft facility will become part of Thermo Fisher's global biologics manufacturing network, including sites in Princeton, NJ and St Louis, MO, US; Groningen, the Netherlands; Brisbane, Australia; and Hangzhou, China.

The new site features highly flexible bioproduction technologies, including single-use and high-volume stainless steel with up to 12,500 L bioreactor capacity to provide a pathway from development to large-scale production as customers' needs increase.

With the addition of more than 200 new colleagues, Thermo Fisher will initially support manufacturing of CSL's next-generation recombinant factor IX product Idelvion for patients with hemophilia B once construction of the site is complete next year.

Michel Lagarde, executive vice president of Thermo Fisher Scientific said the new site will enable customers to "start their projects with us and stay with us as their manufacturing requirements grow."

The strategic partnership between the two companies was forged to help meet the growing demand for biologic therapies while also accelerating CSL's broader manufacturing objectives. Thermo Fisher said that in time, it plans to expand the use of the site to include additional biopharma customers.

Mentioned Companies
Thermo Fisher Scientific Inc.
View company profile

Related News